Current treatment status-Undergoing active treatment-Progressive despite several lines of treatment - Page 6 of 24 Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-Progressive despite several lines of treatment Posts on Medivizor

Searching for patients with EGFR-positive advanced tumors to trial an experimental treatment.

Searching for patients with EGFR-positive advanced tumors to trial an experimental treatment.

Posted by on Nov 22, 2020 in Colorectal cancer | 0 comments

In a nutshell This trial is being carried out to assess the safety and effectiveness of an experimental drug called BCA101 alone and in combination with pembrolizumab (Keytruda) in advanced solid tumors that are EGFR-positive. The main outcomes to be measured are the occurrence of side effects and response to treatment. The details Advanced solid...

Read More

Searching for patients with EGFR-positive advanced tumors to trial an experimental treatment.

Searching for patients with EGFR-positive advanced tumors to trial an experimental treatment.

Posted by on Nov 22, 2020 in Breast cancer | 0 comments

In a nutshell This trial is being carried out to assess the safety and effectiveness of an experimental drug called BCA101 alone and in combination with pembrolizumab (Keytruda) in advanced solid tumors that are EGFR-positive. The main outcomes to be measured are the occurrence of side effects and response to treatment. The details Advanced solid...

Read More

Searching for patients with EGFR-positive advanced tumors to trial an experimental treatment.

Searching for patients with EGFR-positive advanced tumors to trial an experimental treatment.

Posted by on Nov 22, 2020 in Melanoma | 0 comments

In a nutshell This trial is being carried out to assess the safety and effectiveness of an experimental drug called BCA101 alone and in combination with pembrolizumab (Keytruda) in advanced solid tumors that are EGFR-positive. The main outcomes to be measured are the occurrence of side effects and response to treatment. The details Advanced...

Read More

Longer-term outcomes for olaparib in the treatment of advanced castration-resistant prostate cancer

Longer-term outcomes for olaparib in the treatment of advanced castration-resistant prostate cancer

Posted by on Oct 24, 2020 in Prostate cancer | 0 comments

In a nutshell This study evaluated longer-term survival rates and the safety of olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer (mCRPC). It found that treatment with olaparib led to significantly longer survival, especially in men with gene alterations. Some background CRPC is an especially aggressive...

Read More

Osimertinib in EGFR-positive non-small cell lung cancer spread to the brain or the layers surrounding the brain.

Osimertinib in EGFR-positive non-small cell lung cancer spread to the brain or the layers surrounding the brain.

Posted by on Oct 24, 2020 in Lung cancer | 0 comments

In a nutshell This trial was carried out to examine the effectiveness of osimertinib (Tagrisso) in non-small cell lung cancer (NSCLC) that has spread to the brain of the layers of the brain (meninges). The authors concluded that osimertinib showed improved survival and had a good response rate in these patients. Some...

Read More

Evaluating the impact of novel agents on allogeneic stem cell transplant outcomes for chronic lymphocytic leukemia 

Evaluating the impact of novel agents on allogeneic stem cell transplant outcomes for chronic lymphocytic leukemia 

Posted by on Oct 17, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if allogeneic stem cell transplantation (allo-SCT) was a safe and effective option for the treatment of patients with chronic lymphocytic leukemia (CLL) after treatment with novel agents (NA).  This study concluded that this treatment option was safe and effective for patients with...

Read More

Seeking patients with relapsed B-cell NHL or CLL for trial of kinase-blocking treatment

Seeking patients with relapsed B-cell NHL or CLL for trial of kinase-blocking treatment

Posted by on Oct 11, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study will evaluate a three-drug regimen for the treatment of relapsed B-cell non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL). The primary outcomes are how many patients respond to treatment or have a complete response (cancer no longer detectable). The study will take place in the United States. The details B-cell...

Read More

Looking for participants to test an experimental immunotherapy for relapsed non-Hodgkin lymphoma

Looking for participants to test an experimental immunotherapy for relapsed non-Hodgkin lymphoma

Posted by on Oct 11, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study will evaluate the antibody therapy odronextamab for patients with relapsed B-cell non-Hodgkin lymphoma (NHL). The primary outcomes will be how many patients respond to treatment, and how many have a complete response (cancer no longer detectable).  The details For B-cell NHL which has relapsed (returned) after...

Read More

Elotuzumab, lanalidomide and dexamethasone increases overall survival of patients with relapsed or refractory multiple myeloma.

Elotuzumab, lanalidomide and dexamethasone increases overall survival of patients with relapsed or refractory multiple myeloma.

Posted by on Oct 10, 2020 in Multiple Myeloma | 0 comments

In a nutshell This trial was carried out to examine the effectiveness and safety of elotuzumab (Empliciti), lenalidomide (Revlimid), and dexamethasone (Decadron) in relapsed or refractory (unresponsive) multiple myeloma (MM). The authors found that there was an improved survival in these patients in the long-term. Some...

Read More

Ipilimumab and radiotherapy improves survival in patients with metastatic castration-resistant prostate cancer

Ipilimumab and radiotherapy improves survival in patients with metastatic castration-resistant prostate cancer

Posted by on Sep 30, 2020 in Prostate cancer | 0 comments

In a nutshell This trial was carried out to examine the effectiveness of radiotherapy followed by treatment with ipilimumab (Yervoy) in men with metastatic castrate-resistant prostate cancer  (mCRPC). The trial found that this treatment led to higher survival in these patients compared to radiotherapy followed by placebo. Some...

Read More

Long-term outcomes of the combination of ibrutinib, bendamustine and rituximab in relapsed/unresponsive CLL/SLL

Long-term outcomes of the combination of ibrutinib, bendamustine and rituximab in relapsed/unresponsive CLL/SLL

Posted by on Sep 24, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the long-term effectiveness of the combination of ibrutinib, bendamustine, and rituximab in relapsed/unresponsive chronic lymphocytic leukemia/small lymphocytic lymphoma. This study concluded that this combination was safe and effective in the long-term in these patients.   Some background...

Read More